CoChat
Sign Up
Cited by 0Lipoproteins and Cardiovascular HealthLipid metabolism and disordersDiabetes, Cardiovascular Risks, and Lipoproteins

Targeting triglycerides for cardiovascular risk reduction

Open access
Maiorca, Carlo, Tramontano, Daniele, Di Costanzo, Alessia, D’Erasmo, Laura·2026·Internal and Emergency Medicine
DOI 10.1007/s11739-026-04383-1PMC PMC13582088
Open this paper in CoChat — free accountOpen PDF

Abstract

Residual cardiovascular risk persists in many patients despite optimal control of established factors such as low-density lipoprotein cholesterol (LDL-C), blood pressure and glycaemia. Mounting evidence indicates that hypertriglyceridemia (HTG) and triglyceride-rich lipoproteins (TRLs), including their remnant particles, contribute to atherogenesis and therefore constitute actionable targets for risk reduction. This narrative review summarizes current knowledge of TRL metabolism and its role in atherosclerotic cardiovascular disease (ASCVD), drawing on mechanistic studies, observational cohorts and Mendelian-randomization analyses. TRLs display pro-inflammatory and pro-thrombotic properties and are increasingly implicated in plaque initiation and progression. Traditional and emerging therapeutic strategies designed to lower TRL burden are critically examined with particular emphasis on their ability to address residual cardiovascular risk. Conventional interventions, fibrates and mixed omega-3 fatty-acid formulations, have yielded modest and inconsistent cardiovascular benefits. By contrast, icosapent ethyl, a highly purified ethyl ester of eicosapentaenoic acid, is the only TRL-targeted therapy that has demonstrated a significant reduction in major cardiovascular events in a large, randomized trial, irrespective of baseline triglyceride levels. Novel agents such as evinacumab (an ANGPTL3 monoclonal antibody) and antisense oligonucleotides against apolipoprotein C-III (volanesorsen, olezarsen, plozasiran) have produced marked decreases in triglycerides, apoB-containing lipoproteins and remnant cholesterol in recent clinical studies, even though cardiovascular outcome data are not yet available. Therefore, therapies targeting TRL metabolism represent a promising approach to reduce residual cardiovascular risk, particularly in high-risk or statin-treated patients.

AI snapshot

Written from the paper’s full text.

TL;DR

This narrative review argues that triglyceride-rich lipoproteins (TRLs) and their remnants contribute causally to residual atherosclerotic cardiovascular risk beyond LDL-C, and that icosapent ethyl is the only TRL-targeted therapy with proven major cardiovascular event reduction. Novel APOC3- and ANGPTL3-targeted agents markedly lower triglycerides but still lack cardiovascular outcome data.

Key findings

  • TRL remnants (approximately 30–80 nm) can cross the endothelium, be retained in the arterial intima, and promote foam cell formation, inflammation, and thrombosis; observational and Mendelian-randomization evidence links triglycerides and remnant cholesterol to ASCVD independently of LDL-C.
  • Icosapent ethyl 4 g/day reduced MACE by 25% in REDUCE-IT (HR 0.75; 95% CI 0.68–0.83; p < 0.001) among 8,179 statin-treated patients with fasting triglycerides 135–499 mg/dL, with an absolute risk reduction of 4.8% and NNT of 21; mediation analysis attributed approximately 57% of benefit to EPA and nearly 80% jointly to EPA, arachidonic acid, and triglycerides.
  • Fibrates lower triglycerides by 30–50% but have neutral or inconsistent cardiovascular outcome effects overall; mixed EPA+DHA omega-3 formulations also show inconsistent benefit (STRENGTH: HR 0.99; 95% CI 0.90–1.09; p = 0.84).
  • Emerging agents produce large triglyceride reductions—volanesorsen ~77%, olezarsen ~60%, plozasiran ~60–80%, evinacumab ~50–80%—but no cardiovascular outcome data are yet available.

Methods

  • Narrative review synthesizing mechanistic studies, observational cohorts, Mendelian-randomization analyses, and randomized trials, with tables summarizing observational and genetic evidence and pharmacological strategies.
  • No systematic review, meta-analysis, or new primary data collection is described.

Limitations

  • Stated: evidence on the precise relationship between TRLs and systemic inflammatory biomarkers remains sparse; novel TRL-targeted agents lack cardiovascular outcome data; many studies were conducted in rare monogenic disorders and may not reflect broader dyslipidemic populations; the mineral oil placebo in REDUCE-IT raised concerns.
  • Evident: the narrative design lacks a systematic search, quantitative synthesis, and formal risk-of-bias assessment, so conclusions depend on selected evidence and trials.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1007/s11739-026-04383-1

Cites

116 of 117 references verified1 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Claims the paper makes

88 of 151 cited sources checked · 21 supported · 2 flagged · accuracy not yet measured

  • Premisecitation

    Mendelian randomization analyses confirm a causal relationship between lifelong TRL elevation and ASCVD.

    “Observational cohorts demonstrate that higher TG and remnant cholesterol predict cardiovascular events independently of LDL-C, while Mendelian randomization analyses confirm a causal relationship between lifelong TRL elevation and ASCVD.”
    Quote in the paperSubstantial claim8 of 10 sources checked
    • cites [22] Varbo A, Benn M, Tybjærg-Hansen A, Nordestgaard BG (2013) Elevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation. Circulation 128(12):1298–1309. https://doi.org/10.1161/CIRCULATIONAHA.113.003008 source

      In “Risk of IHD: Observational and Causal Associations,” the paper reports a higher estimated risk of ischemic heart disease with genetically higher remnant cholesterol. That supports the causal-inference point, but the study measures remnant cholesterol rather than TRL elevation generally, and its clinical outcome is ischemic heart disease rather than ASCVD broadly. (LLM, conf=0.84)

      Experimental — accuracy not yet measured
    • cites [55] Do R, Willer CJ, Schmidt EM et al (2013) Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet 45(11):1345–1352. https://doi.org/10.1038/ng.2795 source

      The paper’s concluding passage (labelled Abstract in our copy; page unavailable) says its genetic analyses provide evidence that plasma triglycerides likely reflect processes causal for coronary artery disease. Its limitations passage cautions that the variants also affect other lipids and are not ideal Mendelian-randomization instruments. The claim overstates this as confirmation that lifelong elevation of triglyceride-rich lipoproteins (TRLs) itself causes the broader outcome of ASCVD. (LLM, conf=0.88)

      Experimental — accuracy not yet measured
    • cites [56] Björnson E, Adiels M, Taskinen MR et al (2023) Triglyceride-rich lipoprotein remnants, low-density lipoproteins, and risk of coronary heart disease: a UK Biobank study. Eur Heart J 44(39):4186–4195. https://doi.org/10.1093/eurheartj/ehad337 source

      The Results report that genetically defined increases in TRL/remnant cholesterol predict ASCVD outcomes in multivariable Mendelian randomisation models. However, the Introduction describes the association as “likely causal,” not confirmed, and the cited passages do not establish that TRL elevation was lifelong. Page numbers are unavailable in our copy. (LLM, conf=0.85)

      Experimental — accuracy not yet measured
    • cites [57] Navarese EP, Vine D, Proctor S et al (2023) Independent causal effect of remnant cholesterol on atherosclerotic cardiovascular outcomes: a mendelian randomization study. Arterioscler Thromb Vasc Biol 43(9):e373–e380. https://doi.org/10.1161/ATVBAHA.123.319297 source

      The Discussion reports strong Mendelian-randomization evidence that higher remnant cholesterol is causally associated with coronary artery disease and myocardial infarction. The study examines genetically proxied remnant cholesterol, not lifelong elevation of all triglyceride-rich lipoproteins; it also says the stroke association was attenuated in mediation analysis. (LLM, conf=0.84)

      Experimental — accuracy not yet measured
    • cites [58] Zhao Y, Zhuang Z, Li Y et al (2024) Elevated blood remnant cholesterol and triglycerides are causally related to the risks of cardiometabolic multimorbidity. Nat Commun 15(1):2451. https://doi.org/10.1038/s41467-024-46686-x source

      The Results (Mendelian randomization analysis) report causal associations of genetically predicted remnant cholesterol and triglycerides with ischemic heart disease, supporting the claim for that cardiovascular outcome. The Discussion says MR estimates may indicate life-course effects, but the Results report no causal association with stroke; the paper therefore does not establish the broader claim about ASCVD as a whole. (LLM, conf=0.87)

      Experimental — accuracy not yet measured
    • cites [59] Khera AV, Won HH, Peloso GM et al (2017) Association of rare and common variation in the lipoprotein lipase gene with coronary artery disease. JAMA 317(9):937–946. https://doi.org/10.1001/jama.2017.0972 source

      The Results (page unavailable) associate damaging LPL variants with higher triglycerides and remnant cholesterol and greater odds of early-onset coronary artery disease. The Discussion (page unavailable) says lifelong changes in lipoprotein lipase activity are likely to affect coronary risk, but it does not claim to confirm a causal relationship between lifelong elevation of all triglyceride-rich lipoproteins and ASCVD broadly. (LLM, conf=0.86)

      Experimental — accuracy not yet measured
    • cites [60] TG, HDL Working Group of the Exome Sequencing Project, National Heart, Lung, and Blood Institute, Crosby J, Peloso GM, et al. Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med. 2014;371(1):22–31. https://doi.org/10.1056/NEJMoa1307095 source

      The Discussion (page unavailable in our copy) explicitly says that whether triglyceride-rich lipoproteins have a causal effect on coronary heart disease “remains unanswered.” It describes the APOC3 genetic findings as suggesting that a lifelong decrease in triglyceride-rich lipoproteins may be protective, not as confirming the claimed causal relationship. (LLM, conf=0.90)

      Checked by a reasoning model — may be wrong.

      Experimental — accuracy not yet measured
    • cites [61] Nordestgaard BG, Abildgaard S, Wittrup HH, Steffensen R, Jensen G, Tybjaerg-Hansen A (1997) Heterozygous lipoprotein lipase deficiency: frequency in the general population, effect on plasma lipid levels, and risk of ischemic heart disease. Circulation 96(6):1737–1744. https://doi.org/10.1161/01.cir.96.6.1737 source
    • cites [62] Jørgensen AB, Frikke-Schmidt R, West AS, Grande P, Nordestgaard BG, Tybjærg-Hansen A (2013) Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction. Eur Heart J 34(24):1826–1833. https://doi.org/10.1093/eurheartj/ehs431 source
    • cites [63] Ibi D, Boot M, Dollé MET et al (2022) Apolipoprotein A-V is a potential target for treating coronary artery disease: evidence from genetic and metabolomic analyses. J Lipid Res 63(5):100193. https://doi.org/10.1016/j.jlr.2022.100193 source

      The Introduction (page unavailable) reports prior Mendelian randomization analyses linking genetically lower triglycerides via LPL to reduced coronary artery disease risk, and the Results find a similar genetic association. But the Discussion explicitly says this study is not a proper Mendelian randomization test of whether triglycerides cause coronary artery disease. It does not confirm a causal effect of lifelong TRL elevation on ASCVD. (LLM, conf=0.86)

      Experimental — accuracy not yet measured
  • Premisecitation

    Clinical studies have consistently demonstrated that fibrates reduce fasting TG levels by 30-50%, depending on baseline values and the specific agent used.

    “In fact, clinical studies have consistently demonstrated that fibrates reduce fasting TG levels by 30–50%, depending on baseline values and the specific agent used [77].”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [77] Scott R, Best J, Forder P, Taskinen MR, Simes J, Barter P, Keech A, FIELD Study Investigators (2005) Fenofibrate intervention and event lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481]. Cardiovasc Diabetol 4:13. https://doi.org/10.1186/1475-2840-4-13 source

      The Results (page unavailable) report that triglycerides fell by an average of 26% after six weeks of fenofibrate treatment, below the claimed 30–50% range. The Introduction says fibrates lower triglycerides, but the study's measured reduction is a counterexample to the claim that clinical studies consistently demonstrate a 30–50% reduction. (LLM, conf=0.84)

      Checked by a reasoning model — may be wrong.

      Experimental — accuracy not yet measured
  • Premisecitation

    TRL remnants contribute to a prothrombotic phenotype by promoting platelet activation and aggregation and modulating endothelial and systemic hemostatic responses.

    “In addition, TRL remnants contribute to a prothrombotic phenotype within the vascular wall by promoting platelet activation and aggregation, and by modulating both endothelial and systemic hemostatic responses [29–32].”
    Quote in the paperSubstantial claim2 of 4 sources checked
    • cites [29] Doi H, Kugiyama K, Oka H et al (2000) Remnant lipoproteins induce proatherothrombogenic molecules in endothelial cells through a redox- sensitive mechanism. Circulation 102(6):670–676 source

      The Discussion (page not indicated) reports that remnant-like lipoproteins increased endothelial tissue factor expression, supporting an endothelial prothrombotic effect. It also reports higher circulating soluble adhesion molecules in patients with higher remnant levels, but does not show platelet activation or aggregation or establish a systemic hemostatic response. (LLM, conf=0.88)

      Experimental — accuracy not yet measured
    • cites [30] Wang YI, Bettaieb A, Sun C et al (2013) Triglyceride-rich lipoprotein modu- lates endothelial vascular cell adhesion molecule (VCAM)-1 expression via differential regulation of endoplasmic reticulum stress. PLoS ONE 8(10):e78322 source

      The Results and Discussion describe how postprandial triglyceride-rich lipoproteins alter VCAM-1 expression and inflammatory responses in human aortic endothelial cells; they do not address a prothrombotic phenotype. Searches for platelet activation, aggregation, coagulation, and endothelial or systemic hemostatic responses found no passage supporting the attributed claim. The passages have section labels but no page numbers. (LLM, conf=0.76)

      Experimental — accuracy not yet measured
    • cites [31] Olufadi R, Byrne CD (2006) Effects of VLDL and remnant particles on platelets. Pathophysiol Haemost Thromb 35(3–4):281–291 source
    • cites [32] Steffel J, Luscher TF, Tanner FC (2006) Tissue factor in cardiovascular diseases: molecular mechanisms and clinical implications. Circulation 113(5):722–731 source
  • Premisecitation

    Elevated TG and TRLs contribute independently to cardiovascular risk, even in patients achieving LDL-C targets.

    “The recent ESC/EAS 2025 Focused Update Guideline [9] emphasizes that elevated TG and TRLs contribute independently to cardiovascular risk, even in patients achieving LDL-C targets.”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [9] Mach F, Koskinas KC, Roeters van Lennep JE, Tokgözoğlu L, Badimon L, Baigent C, Benn M, Binder CJ, Catapano AL, De Backer GG, Delgado V, Fabin N, Ference BA, Graham IM, Landmesser U, Laufs U, Mihaylova B, Nordestgaard BG, Richter DJ, Sabatine MS, ESC/EAS Scientific Document Group (2025) Focused update of the 2019 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J 46(42):4359–4378. https://doi.org/10.1093/eurheartj/ehaf190 source

      Section 7, “Hypertriglyceridaemia” (page not specified), states that triglyceride levels are associated with cardiovascular risk independently of LDL-C levels. The passage does not specifically establish that triglyceride-rich lipoproteins contribute causally to risk, or address patients who have achieved LDL-C targets. (LLM, conf=0.86)

      Experimental — accuracy not yet measured
  • Premisecitation

    Fibrates have not demonstrated consistent cardiovascular benefit in the overall population.

    “the 2025 ESC/EAS Focused Update [9] emphasizes that consistent cardiovascular benefit has not been demonstrated in the overall population, and fibrate therapy should therefore be reserved for carefully selected patients with persistent hypertriglyceridaemia or features of atherogenic dyslipidemia despite optimal LDL-C lowering”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [9] Mach F, Koskinas KC, Roeters van Lennep JE, Tokgözoğlu L, Badimon L, Baigent C, Benn M, Binder CJ, Catapano AL, De Backer GG, Delgado V, Fabin N, Ference BA, Graham IM, Landmesser U, Laufs U, Mihaylova B, Nordestgaard BG, Richter DJ, Sabatine MS, ESC/EAS Scientific Document Group (2025) Focused update of the 2019 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J 46(42):4359–4378. https://doi.org/10.1093/eurheartj/ehaf190 source
  • May combine two claims. 73
  • Classified as probably not a substantial claim. 9
  • The quote only partly states this claim. 1

  • May combine two claims.

    Premisecitation

    Hypertriglyceridemia may result from impaired clearance of TRLs, most often due to pathogenic variants in the lipolytic pathway, and may be exacerbated by secondary factors such as diabetes, obesity, alcohol use, and certain medications.

    “HTG may result from impaired clearance of TRLs, most often due to pathogenic variants in the lipolytic pathway, ranging from monogenic defects in LPL gene or its cofactors (APOC2, APOA5, LMF1, and GPIHBP1) to polygenic susceptibility, and may be exacerbated by secondary factors such as diabetes, obesity, alcohol use, and certain medications [5, 6].”
    Quote in the paperNot a substantial claim2 of 2 sources checked
    • cites [5] D’Erasmo L, Tramontano D, Di Costanzo A et al (2025) Contemporary management of familial and multifactorial chylomicronemia syndromes in Italy: insights from the National LIPIGEN registry. Arterioscler Thromb Vasc Biol 45(12):2264–2276. https://doi.org/10.1161/ATVBAHA.125.323340 source

      The paper’s introductory passage describes impaired breakdown of triglyceride-rich lipoproteins in familial chylomicronemia caused by variants in LPL or its cofactors, and says diabetes and obesity can amplify genetic effects in multifactorial chylomicronemia. The Discussion also describes severe hypertriglyceridemia without rare pathogenic variants. Our copy does not establish that pathogenic lipolytic-pathway variants are the most common cause of hypertriglyceridemia, or identify alcohol use and medications as exacerbating factors. (LLM, conf=0.86)

      Experimental — accuracy not yet measured
    • cites [6] Berglund L, Brunzell JD, Goldberg AC et al (2012) Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 97(9):2969–2989 source

      The Pathophysiology section says reduced clearance can contribute to hypertriglyceridemia and lists defects in LpL and related proteins; it also describes diabetes, obesity, and alcohol as contributing factors. The Drugs and 2.1 Evidence sections support medication-related exacerbation. However, the guideline does not say pathogenic variants in the lipolytic pathway are the most common cause; its Pathophysiology section also emphasizes excess triglyceride production and common metabolic conditions. Page numbers are unavailable in our copy. (LLM, conf=0.87)

      Experimental — accuracy not yet measured

  • May combine two claims.

    Premisecitation

    As a result of lipolysis, CM are converted into chylomicron remnants, whereas VLDL particles are transformed into IDL and in part into LDL through further delipidation catalyzed by hepatic lipase.

    “As a result of this process, CM are converted into chylomicron remnants, whereas VLDL particles are gradually transformed into intermediate-density lipoproteins (IDL) and, in part, into low-density lipoproteins (LDL) through further delipidation catalyzed by hepatic lipase [11].”
    Quote in the paperNot a substantial claim1 of 1 sources checked
    • cites [11] Ginsberg HN, Packard CJ, Chapman MJ et al (2021) Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society. Eur Heart J 42(47):4791–4806. https://doi.org/10.1093/eurheartj/ehab551 source

  • May combine two claims.

    Premisecitation

    TRLs and their remnants actively participate in lipid retention, cellular activation, and vascular inflammation, contributing to atherosclerotic disease progression.

    “TRLs not only transport lipids but actively participate in a complex interplay of lipid retention, cellular activation, and vascular inflammation, all fundamental drivers of atherosclerotic disease progression [14, 15].”
    Quote in the paperSubstantial claim1 of 2 sources checked
    • cites [14] Borén XJ, Williams KJ (2016) The central role of arterial retention of cholesterol-rich apolipoprotein B–containing lipoproteins in the pathogenesis of atherosclerosis. Curr Opin Lipidol 27(5):473–483. https://doi.org/10.1097/MOL.0000000000000330 source
    • cites [15] Heo JH, Jo SH (2023) Triglyceride-rich lipoproteins and remnant cholesterol in cardiovascular disease. J Korean Med Sci 38(38):e295. https://doi.org/10.3346/jkms.2023.38.e295 source

  • May combine two claims.

    Premisecitation

    Endothelial-bound LPL catalyzes hydrolysis of triglycerides within TRLs, releasing free fatty acids and monoacylglycerols, which induce endothelial dysfunction and local inflammation, stimulating production of proinflammatory cytokines TNF-α, IL-1β, and IL-6.

    “Endothelial-bound lipoprotein lipase (LPL) catalyzes the hydrolysis of triglycerides within TRLs, releasing free fatty acids and monoacylglycerols. These lipolysis products act as bioactive mediators that induce endothelial dysfunction and local inflammation, stimulating the production of proinflammatory cytokines such as tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), and interle”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [18] Xu D, Xie L, Cheng C, Xue F, Sun C (2024) Triglyceride-rich lipoproteins and cardiovascular diseases. Front Endocrinol (Lausanne) 15:1409653. https://doi.org/10.3389/fendo.2024.1409653 source

      Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

      Experimental — accuracy not yet measured

  • May combine two claims.

    Premisecitation

    Sustained production of these cytokines perpetuates vascular inflammation and influences systemic immune responses, linking metabolic dyslipidemia to chronic inflammatory states that exacerbate atherogenesis.

    “Moreover, the sustained production of these cytokines not only perpetuates vascular inflammation but also influences systemic immune responses, linking metabolic dyslipidemia to chronic inflammatory states that exacerbate atherogenesis [19–21].”
    Quote in the paperNot a substantial claim1 of 3 sources checked
    • cites [19] Aung HH, Lame MW, Gohil K, An C-I, Wilson DW, Rutledge JC (2013) Induction of ATF3 gene network by triglyceride-rich lipoprotein lipolysis products increases vascular apoptosis and inflammation. Arterioscler Thromb Vasc Biol 33:2088–2096 source

      The Discussion (page unavailable) reports cytokine induction by triglyceride-rich lipoprotein lipolysis products and concludes that these products can cause vascular inflammation, potentially increasing susceptibility to atherosclerosis. The Results report increased inflammatory gene expression in postprandial blood mononuclear cells. The paper does not establish sustained cytokine production, effects on systemic immune responses, or chronic inflammatory states. (LLM, conf=0.87)

      Experimental — accuracy not yet measured
    • cites [20] Wang L, Gill R, Pedersen TL, Higgins LJ, Newman JW, Rutledge JC (2009) Triglyceride-rich lipoprotein lipolysis releases neutral and oxidized FFAs that induce endothelial cell inflammation. J Lipid Res 50:204–213 source
    • cites [21] Bleda S, de Haro J, Varela C, Ferruelo A, Acin F (2016) Elevated levels of triglycerides and VLDL-cholesterol provoke activation of nlrp1 inflammasome in endothelial cells. Intl J Cardiol 220:52–55 source

  • May combine two claims.

    Premisecitation

    TRL remnants increase expression of plasminogen activator inhibitor-1 (PAI-1), impairing fibrinolytic activity, leading to reduced clot resolution and enhanced thrombus persistence.

    “Moreover, remnants have been shown to increase the expression of plasminogen activator inhibitor-1 (PAI-1), the primary inhibitor of tissue plasminogen activator (tPA), thereby impairing fibrinolytic activity. Elevated PAI-1 levels lead to reduced clot resolution capacity and have been associated with enhanced thrombus persistence, particularly at sites of plaque disruption [29, 30].”
    Quote in the paperSubstantial claim2 of 2 sources checked
    • cites [29] Doi H, Kugiyama K, Oka H et al (2000) Remnant lipoproteins induce proatherothrombogenic molecules in endothelial cells through a redox- sensitive mechanism. Circulation 102(6):670–676 source

      The Discussion (page unavailable) reports that remnant-like particles increased endothelial tissue factor, ICAM-1, and VCAM-1, but does not address PAI-1, fibrinolytic activity, clot resolution, or thrombus persistence. A work listed in the References concerns PAI-1 and oxidized LDL, not remnant lipoproteins. Searches for PAI-1 and fibrinolysis found no passage supporting the attributed mechanism. (LLM, conf=0.78)

      Experimental — accuracy not yet measured
    • cites [30] Wang YI, Bettaieb A, Sun C et al (2013) Triglyceride-rich lipoprotein modu- lates endothelial vascular cell adhesion molecule (VCAM)-1 expression via differential regulation of endoplasmic reticulum stress. PLoS ONE 8(10):e78322 source

      The Results sections on ER stress and VCAM-1 report how TGRL affects endothelial adhesion-molecule expression, not PAI-1 or fibrinolysis. Searches for PAI-1, plasminogen activator, clot resolution, and thrombus persistence found no passage addressing the attributed claim. Page numbers were not available in our copy. (LLM, conf=0.75)

      Experimental — accuracy not yet measured

  • May combine two claims.

    Premisecitation

    Upon entering the arterial intima, TRL remnants are selectively retained through binding to extracellular matrix proteoglycans, prolonging their residence time, and are taken up by resident macrophages via scavenger receptors without requiring oxidative modification.

    “Upon entering the arterial intima, these remnants are selectively retained through binding to extracellular matrix proteoglycans, prolonging their residence time in the subendothelial space. This retention facilitates uptake by resident macrophages via scavenger receptors, without requiring the oxidative modification typical of LDL particles.”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [17] Toth PP (2016) Triglyceride-rich lipoproteins as a causal factor for cardiovascular disease. Vasc Health Risk Manag 12:171–183. https://doi.org/10.2147/VHRM.S104369 source

      Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

      Experimental — accuracy not yet measured

  • May combine two claims.

    Premisecitation

    Non-fasting TG are on average only ~0.3 mmol/L (27 mg/dL) higher than fasting TG and have comparable prognostic value.

    “non-fasting TG are on average only ~ 0.3 mmol/L (27 mg/dL) higher and have comparable prognostic value.”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [67] Mach F, Baigent C (2020) Alberico L Catapano, Konstantinos C Koskinas, Manuela Casula, Lina Badimon, M John Chapman, Guy G De Backer, Victoria Delgado, Brian A Ference, Ian M Graham, Alison Halliday, Ulf Landmesser, Borislava Mihaylova, Terje R Pedersen, Gabriele Riccardi, Dimitrios J Richter, Marc S Sabatine, Marja-Riitta Taskinen, Lale Tokgozoglu, Olov Wiklund, ESC Scientific Document Group, 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology ( source

  • May combine two claims.

    Premisecitation

    Statins reduce plasma TG concentrations, with modest clinically meaningful reductions, particularly in individuals with elevated baseline TG and comorbid metabolic conditions such as type 2 diabetes and obesity.

    “While statins are primarily prescribed for their potent LDL-C-lowering effects, they also exert a modest yet clinically meaningful impact on TG levels and TRLs, making them foundational therapy in patients with high TG and elevated cardiovascular risk [68].”
    • Also stated in: § Statins · boosted
      “Several lines of evidence have consistently shown that statins reduce plasma TG concentrations, particularly in individuals with elevated baseline levels and comorbid metabolic conditions such as type 2 diabetes mellitus and obesity.”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [68] Ginsberg HN (1998) Effects of statins on triglyceride metabolism. Am J Cardiol 81(4A):32B-35B. https://doi.org/10.1016/s0002-9149(98)00035-6. (PMID: 9526811) source

      The Abstract reports that statins lower plasma triglycerides and can reduce VLDL triglycerides by 35–45% in patients with significant hypertriglyceridemia; it also describes their potent LDL-lowering effects. The Conclusions frame extending statin use to a wider group with high triglycerides and coronary risk as a possibility warranting further study, not an established basis for calling them foundational therapy in that group. The passages do not establish a particular benefit in people with type 2 diabetes or obesity. (LLM, conf=0.86)

      Experimental — accuracy not yet measured

  • May combine two claims.

    Premisecitation

    The resulting cytokine milieu promotes endothelial activation and upregulation of adhesion molecules VCAM-1 and ICAM-1, facilitating monocyte recruitment into the arterial wall.

    “The resulting cytokine milieu promotes endothelial activation and upregulation of adhesion molecules, including vascular cell adhesion molecule-1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM-1), thereby facilitating monocyte recruitment into the arterial wall [18].”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [18] Xu D, Xie L, Cheng C, Xue F, Sun C (2024) Triglyceride-rich lipoproteins and cardiovascular diseases. Front Endocrinol (Lausanne) 15:1409653. https://doi.org/10.3389/fendo.2024.1409653 source

      In “TRLs promotes AS by subendothelial accumulation” (Figure 2; page unavailable), the paper says pro-inflammatory TRLs activate the endothelium to express adhesion molecules, leading to monocyte recruitment; the figure identifies VCAM-1 and ICAM-1. It does not say that the resulting cytokine milieu drives that endothelial activation: it attributes the activation directly to TRLs and their remnants. (LLM, conf=0.83)

      Experimental — accuracy not yet measured

  • Classified as probably not a substantial claim.

    Premisecitation

    The joint guideline recognizes TG/TRL-mediated risk as a modifiable component of residual cardiovascular risk.

    “Overall, the joint guideline recognizes TG/TRL-mediated risk as a modifiable component of residual cardiovascular risk, addressed pragmatically through non–HDL-C/apoB targets and selective TG-lowering therapies integrated with intensive LDL-C reduction, with non-fasting testing as the default approach.”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [9] Mach F, Koskinas KC, Roeters van Lennep JE, Tokgözoğlu L, Badimon L, Baigent C, Benn M, Binder CJ, Catapano AL, De Backer GG, Delgado V, Fabin N, Ference BA, Graham IM, Landmesser U, Laufs U, Mihaylova B, Nordestgaard BG, Richter DJ, Sabatine MS, ESC/EAS Scientific Document Group (2025) Focused update of the 2019 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J 46(42):4359–4378. https://doi.org/10.1093/eurheartj/ehaf190 source

  • May combine two claims.

    Premisecitation

    TRL remnants range in diameter from approximately 30 to 80 nm, enabling passage across the endothelial barrier, unlike large chylomicrons whose size often exceeds 1000 nm.

    “Unlike large chylomicrons, whose size often exceeds 1000 nm and restricts transendothelial passage, triglyceride-rich lipoprotein remnants, including chylomicron remnants, VLDL remnants, and IDL, range in diameter from approximately 30 to 80 nm, enabling passage across the endothelial barrier [16].”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [16] Nordestgaard BG (2016) Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease: new insights from epidemiology, genetics, and biology. Circ Res 118(4):547–563. https://doi.org/10.1161/CIRCRESAHA.115.306249 source

      The Biology section (page unavailable) says large chylomicrons are too large to cross the endothelial barrier, while medium-sized triglyceride-rich lipoproteins can enter the arterial intima. The copy identifies VLDL, IDL, and chylomicron remnants as relevant lipoproteins, but does not give the claimed 30–80 nm remnant range or say chylomicrons often exceed 1000 nm. (LLM, conf=0.88)

      Experimental — accuracy not yet measured

  • Classified as probably not a substantial claim.

    Premisecitation

    Current international guidelines (ESC/EAS and ACC/AHA 2018) endorse statins as the first-line pharmacologic intervention in patients with moderate hypertriglyceridemia (150-499 mg/dL), especially in high-risk or very-high-risk patients.

    “Current international guidelines, including the ESC/EAS [67] and ACC/AHA 2018 recommendations [74], endorse statins as the first-line pharmacologic intervention in patients with moderate hypertriglyceridemia (150–499 mg/dL), especially in high-risk or very-high-risk patients.”
    Quote in the paperSubstantial claim2 of 2 sources checked
    • cites [67] Mach F, Baigent C (2020) Alberico L Catapano, Konstantinos C Koskinas, Manuela Casula, Lina Badimon, M John Chapman, Guy G De Backer, Victoria Delgado, Brian A Ference, Ian M Graham, Alison Halliday, Ulf Landmesser, Borislava Mihaylova, Terje R Pedersen, Gabriele Riccardi, Dimitrios J Richter, Marc S Sabatine, Marja-Riitta Taskinen, Lale Tokgozoglu, Olov Wiklund, ESC Scientific Document Group, 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology ( source

      The ESC/EAS recommendations for drug treatment of hypertriglyceridaemia (page not provided) recommend statins as the first drug of choice to reduce cardiovascular risk in high-risk patients with triglycerides above 200 mg/dL. They do not make that first-line recommendation across the full claimed range of 150–499 mg/dL; the separate ACC/AHA citation is not assessed here. (LLM, conf=0.88)

      Experimental — accuracy not yet measured
    • cites [74] Grundy SM, Stone NJ, Bailey AL et al (2019) 2018 AHA/ACC guideline on the management of blood cholesterol. Circulation 139:e1082–e1143. https://doi.org/10.1161/CIR.0000000000000625 source

      Section 4.4 (Primary Prevention) recommends statins as first-line pharmacotherapy and identifies persistent triglycerides ≥175 mg/dL as a factor favoring statins when assessing ASCVD risk. The cited ACC/AHA text does not state that all patients in the claimed 150–499 mg/dL range should receive statins as first-line treatment; its recommendations also depend on factors such as age, LDL-C and overall risk. (LLM, conf=0.85)

      Experimental — accuracy not yet measured

  • May combine two claims.

    Premisecitation

    In the FIELD and ACCORD-Lipid trials, creatinine elevations resolved after treatment discontinuation and were not associated with markers of tubular damage.

    “Consistently, creatinine elevations observed in the FIELD [77] and ACCORD-Lipid [80] trials resolved after treatment discontinuation and were not associated with markers of tubular damage.”
    Quote in the paperNot a substantial claim2 of 2 sources checked
    • cites [77] Scott R, Best J, Forder P, Taskinen MR, Simes J, Barter P, Keech A, FIELD Study Investigators (2005) Fenofibrate intervention and event lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481]. Cardiovasc Diabetol 4:13. https://doi.org/10.1186/1475-2840-4-13 source

      The Results (page not supplied) report that creatinine rose by nearly 13% during fenofibrate treatment and describe the effect as believed to be reversible and harmless. This paper does not report creatinine levels after treatment discontinuation or an assessment of tubular-damage markers, so it does not establish those parts of the FIELD claim. The separate ACCORD-Lipid citation is outside this verdict. (LLM, conf=0.88)

      Experimental — accuracy not yet measured
    • cites [80] Ginsberg HN, Elam MB, Lovato LC, Crouse JR, Leiter LA, Linz P et al (2010) Effects of combination lipid therapy in type 2 diabetes mellitus. New Engl J Med 362(17):1563–1574. https://doi.org/10.1056/NEJMoa1001282 source

      The Results > Safety passage reports that serum creatinine rose in the ACCORD-Lipid fenofibrate group. It does not report that the elevations resolved after treatment discontinuation or assess markers of tubular damage; its mention of FIELD does not establish those findings for that trial. (LLM, conf=0.85)

      Experimental — accuracy not yet measured

  • May combine two claims.

    Premisecitation

    The 2025 ESC/EAS Focused Update confirms statins as the cornerstone therapy for cardiovascular risk reduction in the presence of elevated TG, by targeting LDL-C and modulating TRLs and reducing the atherogenic potential of the lipid profile.

    “The recent 2025 ESC/EAS Focused Update confirms this guidance, emphasizing the persistent role of statins as the cornerstone therapy for cardiovascular risk reduction in the presence of elevated TG, not only by targeting LDL-C but also by modulating TRLs and reducing the atherogenic potential of the lipid profile [9].”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [9] Mach F, Koskinas KC, Roeters van Lennep JE, Tokgözoğlu L, Badimon L, Baigent C, Benn M, Binder CJ, Catapano AL, De Backer GG, Delgado V, Fabin N, Ference BA, Graham IM, Landmesser U, Laufs U, Mihaylova B, Nordestgaard BG, Richter DJ, Sabatine MS, ESC/EAS Scientific Document Group (2025) Focused update of the 2019 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J 46(42):4359–4378. https://doi.org/10.1093/eurheartj/ehaf190 source

      Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

      Experimental — accuracy not yet measured

  • May combine two claims.

    Premisecitation

    In the PROMINENT trial, pemafibrate substantially lowered triglyceride levels without reducing major adverse cardiovascular events in patients with type 2 diabetes.

    “Similar findings were reported in the PROMINENT trial, in which pemafibrate substantially lowered triglyceride levels without reducing major adverse cardiovascular events in patients with type 2 diabetes [81].”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [81] Pradhan AD, Glynn RJ, Fruchart JC et al (2022) Triglyceride lowering with pemafibrate to reduce cardiovascular risk. N Engl J Med 387:1923–1934 source

  • May combine two claims.

    Premisecitation

    Statins decrease hepatic VLDL synthesis, upregulate LDL receptors, and enhance clearance of apoB-containing lipoproteins, including remnant particles.

    “From a mechanistic standpoint, statins decrease hepatic VLDL synthesis, upregulate LDL receptors, and enhance clearance of apoB-containing lipoproteins, including remnant particles [68].”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [68] Ginsberg HN (1998) Effects of statins on triglyceride metabolism. Am J Cardiol 81(4A):32B-35B. https://doi.org/10.1016/s0002-9149(98)00035-6. (PMID: 9526811) source

      The Conclusions (page unavailable) say statins appear to inhibit VLDL assembly and secretion, and the Abstract says they increase hepatic LDL receptors. The review discusses increased remnant removal as a possible mechanism and reports remnant clearance in dysbetalipoproteinemia, but its Conclusions note no increase in VLDL or LDL apoB fractional clearance in the authors’ own studies. The claim presents enhanced clearance of apoB-containing lipoproteins as a general, established effect without that qualification. (LLM, conf=0.86)

      Experimental — accuracy not yet measured

  • May combine two claims.

    Premisecitation

    In the PROVE-IT TIMI 22 trial, atorvastatin 80 mg reduced LDL-C by 51% and TG by 20%, compared with pravastatin 40 mg reductions of 22% and 11%.

    “Likewise, in the PROVE-IT TIMI 22 trial, intensive lipid-lowering with atorvastatin 80 mg reduced LDL-C by 51% and triglycerides by 20%, compared with 22% and 11% reductions with pravastatin (40 mg/day) and was associated with greater protection against death or major cardiovascular events [72].”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [72] Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R et al (2004) Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350(15):1495–1504. https://doi.org/10.1056/NEJMoa040583 source

      The statistical-analysis passage reports 51% and 22% LDL-C reductions at 30 days, but only among patients who had not previously received statins; the citing sentence omits that qualification. The primary-end-point passage supports greater protection against death or a major cardiovascular event with atorvastatin. Our copy gives baseline triglyceride levels but does not report the claimed 20% and 11% triglyceride reductions. (LLM, conf=0.89)

      Experimental — accuracy not yet measured

  • May combine two claims.

    Premisecitation

    Statins possess pleiotropic properties, such as improving endothelial function, reducing vascular inflammation, and stabilizing atherosclerotic plaques.

    “Moreover, statins possess pleiotropic properties, such as improving endothelial function, reducing vascular inflammation, and stabilizing atherosclerotic plaques, which further support their role in mitigating residual risk [73].”
    Quote in the paperNot a substantial claim1 of 1 sources checked
    • cites [73] Liao JK, Laufs U (2005) Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 45(1):89–118. https://doi.org/10.1146/annurev.pharmtox.45.120403.095748 source

  • May combine two claims.

    Premisecitation

    In the STRENGTH trial (2020), omega-3 carboxylic acids (2.2 g EPA + 0.8 g DHA daily) did not significantly reduce MACE in over 13,000 statin-treated patients at high cardiovascular risk with elevated TG (HR 0.99; 95% CI 0.90-1.09; P = 0.84), leading to early termination for futility.

    “The STRENGTH trial (2020), which assessed omega-3 carboxylic acids (2.2 g EPA + 0.8 g DHA daily) in over 13,000 statin-treated patients at high cardiovascular risk with elevated TG, failed to demonstrate a significant reduction in MACE (HR 0.99; 95% CI 0.90–1.09; P = 0.84), leading to early termination for futility [88].”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [88] Nicholls SJ, Lincoff AM, Garcia M et al (2020) Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH randomized clinical trial. JAMA 324(22):2268–2280. https://doi.org/10.1001/jama.2020.22258 source

      Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

      Experimental — accuracy not yet measured

  • May combine two claims.

    Premisecitation

    In the mediation analysis of REDUCE-IT, EPA alone mediated approximately 57% of the risk reduction, and EPA, arachidonic acid, and triglycerides jointly explained nearly 80% of the total treatment effect on MACE.

    “Specifically, EPA alone mediated approximately 57% of the risk reduction, and EPA, arachidonic acid, and triglycerides jointly explained nearly 80% of the total treatment effect on MACE [105].”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [105] European Heart Journal, Volume 44, Issue Supplement_2, November 2023, ehad655.1309, https://doi.org/10.1093/eurheartj/ehad655.1309 source

  • May combine two claims.

    Premisecitation

    The absolute risk reduction in REDUCE-IT was 4.8%, yielding a number needed to treat (NNT) of 21.

    “The absolute risk reduction was 4.8%, yielding a number needed to treat (NNT) of 21.”
    Quote in the paperNot a substantial claim1 of 1 sources checked
    • cites [104] Ridker PM, Rifai N, MacFadyen J et al (2022) Effects of randomized treatment with icosapent ethyl and a mineral oil comparator on interleukin-1β, interleukin-6, C-reactive protein, oxidized low-density lipoprotein cholesterol, homocysteine, lipoprotein(a), and lipoprotein-associated phospholipase A2: a REDUCE-IT biomarker substudy. Circulation 146(5):372–379. https://doi.org/10.1161/CIRCULATIONAHA.122.059410 source

      The Discussion (page unavailable) reports a reduction in cardiovascular events in REDUCE-IT and specifies a 25% relative risk reduction in first events. Our copy does not report a 4.8% absolute risk reduction or an NNT of 21, so it does not support the claimed figures. (LLM, conf=0.82)

      Experimental — accuracy not yet measured

  • May combine two claims.

    Premisecitation

    The cardiovascular efficacy of IPE was robustly demonstrated in the REDUCE-IT trial, which enrolled 8,179 statin-treated patients with either established cardiovascular disease or diabetes plus additional risk factors, and fasting TG levels between 135 and 499 mg/dL.

    “The cardiovascular efficacy of IPE was robustly demonstrated in the REDUCE-IT trial, which enrolled 8,179 statin-treated patients with either established cardiovascular disease or diabetes plus additional risk factors, and fasting TG levels between 135 and 499 mg/dL [104].”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [104] Ridker PM, Rifai N, MacFadyen J et al (2022) Effects of randomized treatment with icosapent ethyl and a mineral oil comparator on interleukin-1β, interleukin-6, C-reactive protein, oxidized low-density lipoprotein cholesterol, homocysteine, lipoprotein(a), and lipoprotein-associated phospholipase A2: a REDUCE-IT biomarker substudy. Circulation 146(5):372–379. https://doi.org/10.1161/CIRCULATIONAHA.122.059410 source

      Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

      Experimental — accuracy not yet measured

  • May combine two claims.

    Interpretationcitation

    The reductions in cardiovascular mortality and non-fatal myocardial infarction with combination EPA + DHA therapy are substantially smaller than those observed with EPA monotherapy, underscoring the limited cardiovascular efficacy of mixed formulations.

    “substantially smaller than those observed with EPA monotherapy, underscoring the limited cardiovascular efficacy of mixed formulations [92].”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [92] Khan SU, Lone AN, Khan MS et al (2021) Effect of omega-3 fatty acids on cardiovascular outcomes: a systematic review and meta-analysis. EClinicalMedicine 38:100997. https://doi.org/10.1016/j.eclinm.2021.100997 source

  • May combine two claims.

    Premisecitation

    These mediators reduce cytokine production (e.g., IL-6, TNF-α), enhance macrophage phagocytosis, and inhibit neutrophil infiltration.

    “These mediators reduce cytokine production (e.g., IL-6, TNF-α), enhance macrophage phagocytosis, and inhibit neutrophil infiltration [100].”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [100] Serhan CN, Chiang N, Dalli J (2015) The resolution code of acute inflammation: novel pro-resolving lipid mediators in resolution. Semin Immunol 27(3):200–215. https://doi.org/10.1016/j.smim.2015.03.004 source

  • May combine two claims.

    Premisecitation

    Biomarker analyses from REDUCE-IT demonstrated that IPE significantly reduced systemic inflammation and oxidative stress, including a 39.9% decrease in hs-CRP, a 13% reduction in oxidized LDL, and an 18% decrease in lipoprotein-associated phospholipase A2 compared with minimal changes in the placebo group.

    “Beyond lipid modification, biomarker analyses from REDUCE-IT [104] demonstrated that IPE significantly reduced systemic inflammation and oxidative stress, including a 39.9% decrease in hs-CRP, a 13% reduction in oxidized LDL, and an 18% decrease in lipoprotein-associated phospholipase A₂ compared with minimal changes in the placebo group.”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [104] Ridker PM, Rifai N, MacFadyen J et al (2022) Effects of randomized treatment with icosapent ethyl and a mineral oil comparator on interleukin-1β, interleukin-6, C-reactive protein, oxidized low-density lipoprotein cholesterol, homocysteine, lipoprotein(a), and lipoprotein-associated phospholipase A2: a REDUCE-IT biomarker substudy. Circulation 146(5):372–379. https://doi.org/10.1161/CIRCULATIONAHA.122.059410 source

      The biomarker table (Discussion, p. not provided) reports a 39.91% between-group difference in hsCRP at 24 months, but not a 39.9% decrease within the IPE group. It does not report 13% and 18% IPE reductions in oxidized LDL and Lp-PLA2; both changed minimally in the IPE group while increasing in the mineral-oil group. The Discussion explicitly summarizes the pattern as minimal effects with IPE and increases with the comparator, contrary to the claim's account of minimal placebo changes. (LLM, conf=0.90)

      Experimental — accuracy not yet measured

  • May combine two claims.

    Premisecitation

    These structural changes promote nitric oxide (NO) bioavailability and reduce endothelial expression of adhesion molecules such as VCAM-1 and ICAM-1, limiting monocyte adhesion and vascular inflammation.

    “These structural changes promote nitric oxide (NO) bioavailability and reduce endothelial expression of adhesion molecules such as VCAM-1 and ICAM-1, limiting monocyte adhesion and vascular inflammation [98].”
    Quote in the paperNot a substantial claim1 of 1 sources checked
    • cites [98] Calder PC (2017) Omega-3 fatty acids and inflammatory processes: from molecules to man. Biochem Soc Trans 45(5):1105–1115. https://doi.org/10.1042/BST20160474 source

      The section ‘Omega-3 fatty acids, inflammatory signalling and inflammatory proteins’ reports reduced VCAM-1 and ICAM-1 expression on cultured endothelial cells and monocytes. The References section also lists a study of reduced monocyte adhesion to endothelial cells. Neither passage establishes that the cited structural changes cause these effects, and the paper passages found do not address NO bioavailability; page numbers were not supplied. (LLM, conf=0.84)

      Experimental — accuracy not yet measured

  • May combine two claims.

    Premisecitation

    In the meta-analysis by Khan et al. (38 randomized trials, n = 149,051), combination EPA + DHA therapy produced modest but statistically significant reductions in cardiovascular mortality (RR 0.94; 95% CI 0.89-0.99; p = 0.02) and non-fatal myocardial infarction (RR 0.92; 95% CI 0.85-1.00; p = 0.04).

    “in which combination EPA + DHA therapy produced only modest but statistically significant reductions in cardiovascular mortality (RR 0.94; 95% CI 0.89–0.99; p = 0.02) and non-fatal myocardial infarction (RR 0.92; 95% CI 0.85–1.00; p = 0.04)”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [92] Khan SU, Lone AN, Khan MS et al (2021) Effect of omega-3 fatty acids on cardiovascular outcomes: a systematic review and meta-analysis. EClinicalMedicine 38:100997. https://doi.org/10.1016/j.eclinm.2021.100997 source

      Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

      Experimental — accuracy not yet measured

  • May combine two claims.

    Premisecitation

    Over a median follow-up of 4.9 years, IPE significantly reduced the risk of MACE by 25% (HR 0.75; 95% CI 0.68-0.83; p < 0.001), with consistent reductions across all major components, including cardiovascular death, myocardial infarction, stroke, and coronary revascularization.

    “Over a median follow-up of 4.9 years, IPE significantly reduced the risk of MACE by 25% (HR 0.75; 95% CI 0.68–0.83; p < 0.001), with consistent reductions across all major components, including cardiovascular death, myocardial infarction, stroke, and coronary revascularization.”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [104] Ridker PM, Rifai N, MacFadyen J et al (2022) Effects of randomized treatment with icosapent ethyl and a mineral oil comparator on interleukin-1β, interleukin-6, C-reactive protein, oxidized low-density lipoprotein cholesterol, homocysteine, lipoprotein(a), and lipoprotein-associated phospholipase A2: a REDUCE-IT biomarker substudy. Circulation 146(5):372–379. https://doi.org/10.1161/CIRCULATIONAHA.122.059410 source

      The Methods report a median follow-up of 4.9 years and list the events included in the composite outcome. The introductory passage reports a 25% reduction in first major adverse ischemic events (HR 0.75, 95% CI 0.68–0.83; P<0.001). Neither passage establishes that reductions were consistent across each listed component. (LLM, conf=0.88)

      Experimental — accuracy not yet measured

  • May combine two claims.

    Premisecitation

    The VITAL trial noted a modest reduction in myocardial infarction, but overall cardiovascular risk was unaffected.

    “Although results from the VITAL trial noted a modest reduction in myocardial infarction, the overall cardiovascular risk was unaffected [91].”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [91] Manson JE, Bassuk SS, Buring JE, VITAL Research Group (2020) Principal results of the VITamin D and OmegA-3 TriaL (VITAL) and updated meta-analyses of relevant vitamin D trials. J Steroid Biochem Mol Biol 198:105522. https://doi.org/10.1016/j.jsbmb.2019.105522 source

      The ‘Vitamin D and Cardiovascular Disease—VITAL results’ section reports no reduction in major cardiovascular events, supporting the overall-risk portion of the claim. It also says vitamin D did not reduce myocardial infarction (HR 0.96, 95% CI 0.78–1.19), so the claim’s suggestion of a myocardial-infarction benefit is not supported by the results reported here. (LLM, conf=0.85)

      Experimental — accuracy not yet measured

  • May combine two claims.

    Premisecitation

    Elevated apoC-III levels are associated with increased circulating TG, impaired remnant clearance, and a heightened burden of atherogenic lipoproteins.

    “Elevated apoC-III levels are associated with increased circulating TG, impaired remnant clearance, and a heightened burden of atherogenic lipoproteins.”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [111] Borén J, Packard CJ, Taskinen MR (2020) The roles of ApoC-III on the metabolism of triglyceride-rich lipoproteins in humans. Front Endocrinol (Lausanne) 11:474. https://doi.org/10.3389/fendo.2020.00474 source

  • May combine two claims.

    Premisecitation

    In a phase 2 trial (NCT03452228), intravenous evinacumab 15 mg/kg every 4 weeks resulted in highly variable, but sometimes marked TG reductions, up to 70-80%, in patients with multifactorial chylomicronemia without LPL loss-of-function variants, whereas modest effect was observed in those with complete LPL deficiency.

    “In a phase 2 trial (NCT03452228) [108], intravenous evinacumab 15 mg/kg every 4 weeks resulted in highly variable, but sometimes marked TG reductions, up to 70–80%, in patients with multifactorial chylomicronemia without LPL loss-of-function variants, whereas modest effect was observed in those with complete LPL deficiency.”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [108] Rosenson RS, Gaudet D, Ballantyne CM et al (2023) Evinacumab in severe hypertriglyceridemia with or without lipoprotein lipase pathway mutations: a phase 2 randomized trial. Nat Med 29(3):729–737. https://doi.org/10.1038/s41591-023-02222-w source

      Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

      Experimental — accuracy not yet measured

  • May combine two claims.

    Premisecitation

    In the phase 3 BALANCE trial in patients with FCS, olezarsen 80 mg reduced apoC-III by 74% and TG by 43% at 6 months, reaching 59% at 12 months, while markedly lowering the incidence of acute pancreatitis compared with placebo (rate ratio 0.12; 95% CI 0.02-0.66).

    “In the phase 3 BALANCE trial [116], conducted in patients with FCS, olezarsen 80 mg reduced apoC-III by 74% and TG by 43% at 6 months, reaching 59% at 12 months, while markedly lowering the incidence of acute pancreatitis compared with placebo (rate ratio 0.12; 95% CI 0.02–0.66).”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [116] Stroes ESG, Alexander VJ, Karwatowska-Prokopczuk E et al (2024) Olezarsen, acute pancreatitis, and Familial Chylomicronemia Syndrome. N Engl J Med 390(19):1781–1792. https://doi.org/10.1056/NEJMoa2400201 source

      Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

      Experimental — accuracy not yet measured

  • May combine two claims.

    Premisecitation

    Beyond inhibiting LPL, apoC-III delays hepatic uptake of TRL remnants, contributing to both hypertriglyceridemia and atherosclerotic progression through LPL-independent pathways.

    “beyond its inhibitory action on lipoprotein lipase (LPL), apoC-III also delays hepatic uptake of TRL remnants, contributing to both hypertriglyceridemia and atherosclerotic progression through LPL-independent pathways [111]”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [111] Borén J, Packard CJ, Taskinen MR (2020) The roles of ApoC-III on the metabolism of triglyceride-rich lipoproteins in humans. Front Endocrinol (Lausanne) 11:474. https://doi.org/10.3389/fendo.2020.00474 source

  • May combine two claims.

    Premisecitation

    In the ESSENCE-TIMI 73b trial, olezarsen produced placebo-adjusted reductions of approximately 60% in triglycerides and 70% in apoC-III, along with significant decreases in non-HDL cholesterol (−22%) and apoB (−15%) and increases in HDL-C (+46%), without raising LDL-C.

    “In the ESSENCE–TIMI 73b trial [117], which enrolled over 1300 statin-treated patients with moderate HTG, olezarsen produced placebo-adjusted reductions of approximately 60% in triglycerides and 70% in apoC-III, along with significant decreases in non–HDL cholesterol (− 22%) and apoB (− 15%) and increases in HDL-C (+ 46%), without raising LDL-C.”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [117] Bergmark BA, Marston NA, Prohaska TA et al (2025) Targeting APOC3 with Olezarsen in moderate hypertriglyceridemia. N Engl J Med 393(13):1279–1291. https://doi.org/10.1056/NEJMoa2507227 source

  • May combine two claims.

    Premisecitation

    In a phase 2b study (NCT04863014) in patients with severe HTG and a history of pancreatitis, evinacumab 20 mg/kg confirmed a substantial median TG decrease of 55% at week 4 and >90% at week 16, together with consistent improvements in non-HDL cholesterol and ApoC-III levels.

    “A subsequent phase 2b study (NCT04863014) [109] in patients with severe HTG and a history of pancreatitis confirmed a substantial median TG decrease of 55% at week 4 and > 90% at week 16 with the 20 mg/kg dose, together with consistent improvements in non-HDL cholesterol and ApoC-III levels.”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [109] Rosenson RS, George RT, Sanchez RJ et al (2025) Efficacy of evinacumab in patients with severe hypertriglyceridemia and a history of severe hypertriglyceridemia-related acute pancreatitis: a phase 2b trial. J Clin Lipidol. https://doi.org/10.1016/j.jacl.2025.07.005 source

      Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

      Experimental — accuracy not yet measured

  • May combine two claims.

    Premisecitation

    Residual cardiovascular risk is multifactorial, involving elevated lipoprotein(a), chronic low-grade inflammation, and persistent elevations in triglyceride-rich lipoproteins.

    “This risk is increasingly recognized as multifactorial, involving elements such as elevated lipoprotein(a), chronic low-grade inflammation (e.g., high-sensitivity C-reactive protein), and persistent elevations in triglyceride-rich lipoproteins (TRLs) [2].”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [2] Mach F, Visseren FLJ, Cater NB et al (2024) Addressing residual risk beyond statin therapy: new targets in the management of dyslipidaemias-a report from the European society of cardiology cardiovascular round table. J Clin Lipidol 18(5):e685–e700. https://doi.org/10.1016/j.jacl.2024.07.001 source

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Premisecitation

    Hepatocytes continuously secrete VLDL particles containing apolipoprotein B100, incorporating TG derived from de novo lipogenesis, circulating non-esterified fatty acids, hepatic lipid stores, and remnant uptake.

    “In parallel, hepatocytes continuously secrete VLDL particles containing apolipoprotein B100, incorporating TG derived from de novo lipogenesis, circulating non-esterified fatty acids, hepatic lipid stores, and remnant uptake [10].”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [10] Borén J, Taskinen MR, Björnson E, Packard CJ (2022) Metabolism of triglyceride-rich lipoproteins in health and dyslipidaemia. Nat Rev Cardiol 19(9):577–592. https://doi.org/10.1038/s41569-022-00676-y source

  • May combine two claims.

    Interpretationcitation

    Hypertriglyceridemia and triglyceride-rich lipoproteins, including remnant particles, contribute to atherogenesis.

    “TRLs and their remnants are increasingly recognized as causal drivers of atherosclerosis. Genetic, epidemiologic, and mechanistic studies have established their contribution to atherogenic risk, supporting TG lowering as a promising strategy to address residual cardiovascular risk [8].”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [8] Nordestgaard BG, Varbo A (2014) Triglycerides and cardiovascular disease. Lancet 384(9943):626–635. https://doi.org/10.1016/S0140-6736(14)61177-6 source

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Premisecitation

    In the postprandial state, CM are assembled in enterocytes through packaging of dietary TG, cholesterol, and apolipoprotein B48.

    “In the postprandial state, CM are assembled in enterocytes through the packaging of dietary TG, cholesterol, and apolipoprotein B48 [10].”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [10] Borén J, Taskinen MR, Björnson E, Packard CJ (2022) Metabolism of triglyceride-rich lipoproteins in health and dyslipidaemia. Nat Rev Cardiol 19(9):577–592. https://doi.org/10.1038/s41569-022-00676-y source

  • May combine two claims.

    Premisecitation

    Hypertriglyceridemia is a risk factor for acute pancreatitis, with risk progressively increasing with TG > 500 mg/dL and markedly elevated when levels exceed 1000 mg/dL.

    “HTG is a well-known risk factor for acute pancreatitis (AP), depending on TG levels, where the risk progressively increases with TG > 500 mg/dL and is markedly elevated when levels exceed 1000 mg/dL [7].”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [7] Fortson MR, Freedman SN, Webster PD 3rd (1995) Clinical assessment of hyperlipidemic pancreatitis. Am J Gastroenterol 90(12):2134–2139

  • Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

    Premisecitation

    TRLs, primarily chylomicrons and VLDL, are secreted by the intestine and liver, respectively, and are the main vehicles for TG transport in the circulation.

    “TRLs, primarily chylomicrons (CM) and very low-density lipoproteins (VLDL), are secreted by the intestine and liver, respectively, and are the main vehicles for TG transport in the circulation.”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [10] Borén J, Taskinen MR, Björnson E, Packard CJ (2022) Metabolism of triglyceride-rich lipoproteins in health and dyslipidaemia. Nat Rev Cardiol 19(9):577–592. https://doi.org/10.1038/s41569-022-00676-y source

  • Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

    Interpretationnone given

    Evidence on the precise relationship between TRLs and systemic inflammatory biomarkers remains sparse and requires further clarification.

    “However, evidence remains sparse, and the precise relationship between TRLs and systemic inflammatory biomarkers requires further clarification.”
    Quote in the paperNot a substantial claim

  • May combine two claims.

    Premisenone given

    Fibrates have neutral overall cardiovascular outcome data, with benefit in high TG/low HDL subgroups.

    “Fibrates | PPAR-α activation → ↑ LPL activity, ↓ apoC-III, ↑ FA oxidation | ~ 30–50% | ↓ non-HDL-C, modest ↓ apoB | Neutral overall; benefit in high TG/low HDL subgroups”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Premisenone given

    Volanesorsen reduces TG by ~77%, apoB by ~20%, and non-HDL-C by ~46%.

    “Volanesorsen (ASO) | ↓ apoC-III → ↑ TRL clearance, ↓ hepatic VLDL | ~ 77% | ↓ apoB (~ 20%)↓ non-HDL-C (~ 46%) | No outcome data yet”
    Quote in the paperNot a substantial claim

  • Classified as probably not a substantial claim.

    Interpretationreasoning

    This consistent signal across methodologies provides a strong rationale for therapeutic strategies aimed at reducing TRL burden through enhanced lipolysis, remnant clearance, or inhibition of key modulators such as APOC3 and ANGPTL3/4.

    “This consistent signal across methodologies provides a strong rationale for therapeutic strategies aimed at reducing TRL burden through enhanced lipolysis, remnant clearance, or inhibition of key modulators such as APOC3 and ANGPTL3/4.”
    Quote in the paperSubstantial claim
    • Rests on an assumption: Lowering triglyceride-rich lipoproteins reduces cardiovascular risk.
    • Rests on an assumption: The causal relationship between genetically elevated TRLs and ASCVD can be extrapolated to pharmacological lowering of TRLs.

  • May combine two claims.

    Premisenone given

    Olezarsen reduces TG by ~60%, apoB by ~15%, and non-HDL-C by ~22%.

    “Olezarsen (ASO) | ↓ apoC-III → ↑ TRL clearance, ↓ hepatic VLDL | ~ 60% | ↓ apoB (~ 15%)↓ non-HDL-C (~ 22%) | No outcome data yet”
    Quote in the paperNot a substantial claim

  • May combine two claims.

    Premisenone given

    Plozasiran reduces TG by ~60-80%, apoB by ~10-20%, and non-HDL-C by ~20%.

    “Plozasiran (siRNA) | ↓ apoC-III → ↑ TRL clearance, ↓ hepatic VLDL | ~ 60—80% | ↓ apoB (~ 10—20%)↓ non-HDL-C (~ 20%) | No outcome data yet”
    Quote in the paperNot a substantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing), S4 (based). May combine two claims. The quote only partly states this claim.

    Premisenone given

    MTP inhibitors, FGF21 analogues, evinacumab, volanesorsen, olezarsen, and plozasiran have no cardiovascular outcome data.

    “Evinacumab | Inhibits ANGPTL3 → ↑ LPL activity (partly LPL-independent) | ~ 50–80% | Moderate to marked ↓ apoB and ↓ non-HDL-C | No outcome data yet”
    Quote in the paperNot a substantial claim

  • May combine two claims.

    Premisecitation

    The LENS study demonstrated significant reductions in retinopathy progression with fenofibrate, with benefits observed even when glycemic control and traditional lipid measures are accounted for.

    “Dedicated trials, including the Lowering Events in Non-Proliferative Retinopathy in Scotland (LENS) study, have demonstrated significant reductions in retinopathy progression with fenofibrate, with benefits observed even when glycemic control and traditional lipid measures are accounted for, raising the possibility of direct retinal effects independent of triglyceride lowering [84].”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [84] Pirillo A, Zambon A, Catapano AL (2025) Fibrates : do they still have a role in therapy in 2025? Curr Atheroscler Rep 28(1):4. https://doi.org/10.1007/s11883-025-01379-8. (PMID: 41452383.) source

  • May combine two claims.

    Interpretationreasoning

    PPAR-α activation leads to enhanced catabolism of TRLs, increased HDL cholesterol synthesis, and decreased hepatic production of VLDL and apolipoprotein C-III.

    “This leads to enhanced catabolism of TRLs, increased HDL cholesterol synthesis, and decreased hepatic production of VLDL and apolipoprotein C-III, a natural inhibitor of lipoprotein lipase.”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Premisecitation

    Omega-3 fatty acids exert metabolic effects by reducing hepatic VLDL production, enhancing β-oxidation, and modulating inflammatory signaling.

    “They exert their metabolic effects by reducing hepatic production of very-low-density lipoproteins (VLDL), enhancing β-oxidation, and modulating inflammatory signaling [85].”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [85] Endres S, Meydani SN, Ghorbani R, Schindler R, Dinarello CA. Dietary supplementation with n-3 fatty acids suppresses interleukin-2 production and mononuclear cell proliferation. J Leukoc Biol. 1993;54(6):599–603. https://doi.org/10.1002/jlb.54.6.599 source

  • May combine two claims.

    Premisecitation

    In the VOYAGER meta-analysis of 32 randomized controlled trials involving over 37,000 patients, statin therapy leads to dose-dependent reductions in TG levels ranging from 10 to 30%, with greater reductions in those with baseline TG ≥ 200 mg/dL.

    “The VOYAGER meta-analysis, which synthesized data from 32 randomized controlled trials involving over 37,000 patients, demonstrated that statin therapy leads to dose-dependent reductions in TG levels ranging from 10 to 30%, with greater reductions observed in those with baseline TG ≥ 200 mg/dL [69].”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [69] Karlson BW, Palmer MK, Nicholls SJ, Lundman P, Barter PJ (2016) A VOYAGER Meta-Analysis of the impact of statin therapy on low-density lipoprotein cholesterol and triglyceride levels in patients with hypertriglyceridemia. Am J Cardiol 117(9):1444–1448. https://doi.org/10.1016/j.amjcard.2016.02.011. (Epub 2016 Feb 17 PMID: 26969416) source

  • May combine two claims.

    Premisecitation

    In the GREACE study, atorvastatin (10-80 mg/day) reduced LDL-C by 41% and TG by 28% in patients with metabolic syndrome.

    “In the GREACE study [70], statin therapy with atorvastatin (10–80 mg/day) reduced LDL-C by 41% and TG by 28% in patients with metabolic syndrome, leading to improved cardiovascular outcomes.”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [70] Mikhailidis DP, Wierzbicki AS (2002) The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Curr Med Res Opin 18(4):215–219. https://doi.org/10.1185/030079902125000778 source

  • May combine two claims.

    Premisecitation

    The risk of muscle-related side effects is markedly increased with gemfibrozil due to pharmacokinetic interactions, whereas fenofibrate is considered safer when combined with statins.

    “This risk is markedly increased with gemfibrozil due to pharmacokinetic interactions, whereas fenofibrate is considered safer when combined with statins [78].”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [78] Davidson MH (2006) Safety profile of fenofibrate. Am J Cardiol 97(2A):19C – 24

      Couldn’t be matched to a paper in Crossref, so it can’t be checked.

  • May combine two claims.

    Premisecitation

    Fibrates are generally well tolerated, although hepatic, muscular, and renal adverse effects require clinical attention.

    “Fibrates are generally well tolerated, although hepatic, muscular, and renal adverse effects require clinical attention [78].”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [78] Davidson MH (2006) Safety profile of fenofibrate. Am J Cardiol 97(2A):19C – 24

      Couldn’t be matched to a paper in Crossref, so it can’t be checked.

  • May combine two claims.

    Premisecitation

    In the JUPITER trial, rosuvastatin reduced LDL-C by 50% and TG by 17% in primary prevention patients with normal LDL-C but elevated hs-CRP.

    “The JUPITER trial, which enrolled primary prevention patients with normal LDL-C but elevated hs-CRP, showed that rosuvastatin not only reduced LDL-C by 50% but also lowered TG by 17%, suggesting a dual benefit in patients with residual dyslipidemia [71].”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [71] Ridker PM, Danielson E, Fonseca FAH, Genest J, Gotto AM Jr, Kastelein JJP et al (2008) Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359(21):2195–2207. https://doi.org/10.1056/NEJMoa0807646 source

  • May combine two claims.

    Interpretationreasoning

    Overall, fibrates are highly effective triglyceride-lowering agents, but their impact on cardiovascular outcomes remains modest and confined to selected patient populations.

    “Overall, fibrates are highly effective triglyceride-lowering agents, but their impact on cardiovascular outcomes remains modest and confined to selected patient populations.”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Interpretationcitation

    These effects were proportional to achieved plasma EPA concentrations rather than TG lowering, underscoring EPA's pleiotropic effects.

    “These effects were proportional to achieved plasma EPA concentrations rather than TG lowering, underscoring EPA’s pleiotropic effects.”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Premisecitation

    The clinical benefit of EPA monotherapy was first demonstrated by the JELIS study, which enrolled 18,645 hypercholesterolemic patients receiving statin therapy.

    “The clinical benefit of EPA monotherapy was first demonstrated by the JELIS study [101], which enrolled 18,645 hypercholesterolemic patients receiving statin therapy.”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [101] Yokoyama M, Origasa H, Matsuzaki M et al (2007) Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 369(9567):1090–1098. https://doi.org/10.1016/S0140-6736(07)60527-3 source

  • May combine two claims.

    Premisecitation

    Daily administration of 1.8 g of EPA led to a 19% relative reduction in MACE (p = 0.011), despite baseline TG levels within the normal range (median 153 mg/dL).

    “Daily administration of 1.8 g of EPA led to a 19% relative reduction in MACE (p = 0.011), despite baseline TG levels within the normal range (median 153 mg/dL).”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [101] Yokoyama M, Origasa H, Matsuzaki M et al (2007) Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 369(9567):1090–1098. https://doi.org/10.1016/S0140-6736(07)60527-3 source

  • May combine two claims.

    Interpretationreasoning

    The absence of DHA in IPE avoids potential counteractive effects of DHA on LDL-cholesterol and membrane structure, which may have attenuated efficacy in the mixed formulation tested in STRENGTH.

    “the absence of DHA in IPE avoids potential counteractive effects of DHA on LDL-cholesterol and membrane structure, which may have attenuated efficacy in the mixed formulation tested in STRENGTH”
    Quote in the paperSubstantial claim
    • Rests on an assumption: DHA has counteractive effects on LDL-cholesterol and membrane structure.

  • May combine two claims.

    Premisecitation

    In a recent multicenter, double-blind randomized trial in patients on maintenance hemodialysis, daily fish-oil supplementation (4 g of n-3 polyunsaturated fatty acids [1.6 g EPA and 0.8 g DHA]) over a median follow-up of 3.5 years significantly reduced the risk of major cardiovascular events, including myocardial infarction, stroke, and cardiovascular death, compared with placebo.

    “Over a median follow-up of 3.5 years, fish-oil significantly reduced the risk of major cardiovascular events, including myocardial infarction, stroke, and cardiovascular death, compared with placebo.”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [93] Lok CE, Farkouh M, Hemmelgarn BR, Moist LM, Polkinghorne KR, Tomlinson G, Tam P, Tonelli MA, Udell JA et al (2025) Fish_Oil supplementation and cardiovascular events in patients receiving hemodialysis. N Engl J Med. https://doi.org/10.1056/NEJMoa2513032 source

  • May combine two claims.

    Premisecitation

    In the ANCHOR study, which enrolled statin-treated patients with persistently high TG (200-499 mg/dL), IPE 4 g/day reduced TG by 22%, ApoB by 9%, and hs-CRP by 36%, while significantly increasing plasma EPA by more than six-fold and lowering the arachidonic-acid/EPA ratio by 91%.

    “In ANCHOR study, which enrolled statin-treated patients with persistently high TG (200–499 mg/dL), IPE 4 g/day reduced TG by 22%, ApoB by 9%, and hs-CRP by 36%, while significantly increasing plasma EPA by more than six-fold and lowering the arachidonic-acid/EPA ratio by 91%.”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [103] Ballantyne CM, Bays HE, Kastelein JJ et al (2012) Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study). Am J Cardiol 110(7):984–992. https://doi.org/10.1016/j.amjcard.2012.05.031 source

  • May combine two claims.

    Premisecitation

    The RESPECT-EPA trial, conducted in statin-treated Japanese patients with stable coronary artery disease and a low baseline EPA-to-arachidonic acid ratio, showed a numerically lower incidence of major cardiovascular events with icosapent ethyl that did not reach statistical significance for the primary end point, although a significant reduction was observed in the secondary composite of coronary

    “Similarly, the RESPECT-EPA trial [107], conducted in statin-treated Japanese patients with stable coronary artery disease and a low baseline EPA-to–arachidonic acid ratio, showed a numerically lower incidence of major cardiovascular events with icosapent ethyl that did not reach statistical significance for the primary end point, although a significant reduction was observed in the secondary”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [107] Miyauchi K, Iwata H, Nishizaki Y et al (2024) Randomized trial for evaluation in secondary prevention efficacy of combination therapy-statin and eicosapentaenoic acid (RESPECT-EPA). Circulation 150(6):425–434. https://doi.org/10.1161/CIRCULATIONAHA.123.065520 source

  • May combine two claims.

    Premisecitation

    In the MARINE study, conducted in patients with very high TG (≥ 500 mg/dL), IPE 4 g/day lowered TG levels by 33% without increasing LDL-C or ApoB, and significantly reduced large VLDL (28%) and small LDL (26%) particle concentrations.

    “In MARINE study, conducted in patients with very high TG (≥ 500 mg/dL), IPE 4 g/day lowered TG levels by 33% without increasing LDL-C or ApoB, and significantly reduced large VLDL (28%) and small LDL (26%) particle concentrations.”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [102] Bays HE, Braeckman RA, Ballantyne CM et al (2012) Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on lipoprotein particle concentration and size in patients with very high triglyceride levels (the MARINE study). J Clin Lipidol 6(6):565–572. https://doi.org/10.1016/j.jacl.2012.07.001 source

  • May combine two claims.

    Interpretationcitation

    This compositional specificity is clinically meaningful, as trials of pure EPA have consistently demonstrated cardiovascular benefits that were not observed with combined EPA + DHA formulations.

    “This compositional specificity is clinically meaningful, as trials of pure EPA have consistently demonstrated cardiovascular benefits that were not observed with combined EPA + DHA formulations.”
    Quote in the paperNot a substantial claim

  • May combine two claims.

    Interpretationreasoning

    Emerging therapies for severe HTG have profound effects on TG metabolism and remnant lipoproteins, suggesting potential applications in mixed dyslipidemias and atherogenic residual risk.

    “their profound effects on TG metabolism and remnant lipoproteins suggest potential applications in mixed dyslipidemias and atherogenic residual risk”
    Quote in the paperSubstantial claim

  • Probably not a substantial claim: may not pass S4 (based). May combine two claims.

    Interpretationreasoning

    Despite these biologically plausible mechanisms, the inconsistent cardiovascular benefit observed with mixed EPA + DHA formulations may be attributed to the heterogeneity in patient populations, differences in omega-3 pharmacokinetics, and potential antagonism between EPA and DHA.

    “Despite these biologically plausible mechanisms, the inconsistent cardiovascular benefit observed with mixed EPA + DHA formulations may be attributed to the heterogeneity in patient populations, differences in omega-3 pharmacokinetics, and potential antagonism between EPA and DHA.”
    Quote in the paperNot a substantial claim
    • Rests on an assumption: DHA has been shown in some studies to modestly increase LDL-C levels, potentially offsetting some of EPA's anti-inflammatory and lipid-modifying benefits.

  • May combine two claims.

    Premisenone given

    Olezarsen achieves potent, durable, and hepatocyte-selective inhibition of apoC-III synthesis.

    “Olezarsen, a next-generation GalNAc-conjugated ASO targeting hepatic APOC3 mRNA, achieves potent, durable, and hepatocyte-selective inhibition of apoC-III synthesis.”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Premisecitation

    In the phase 3 PALISADE trial, plozasiran reduced apoC-III by ~90% and TG by 78-80% at 10 months, achieving TG levels <500 mg/dL in about half of patients and <150 mg/dL in over 90% of those with partial LPL activity.

    “In the phase 3 PALISADE trial [118], plozasiran reduced apoC-III by ~ 90% and TG by 78–80% at 10 months, achieving TG levels < 500 mg/dL in about half of patients and < 150 mg/dL in over 90% of those with partial LPL activity.”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [118] Watts GF, Rosenson RS, Hegele RA et al (2025) Plozasiran for managing persistent chylomicronemia and pancreatitis risk. N Engl J Med 392(2):127–137. https://doi.org/10.1056/NEJMoa2409368 source

  • May combine two claims.

    Interpretationreasoning

    Broader lipid improvements with evinacumab suggest a potential role in cardiovascular risk reduction, particularly in patients with mixed dyslipidemia or persistently elevated TRLs despite statin therapy.

    “These broader lipid improvements suggest a potential role in cardiovascular risk reduction, particularly in patients with mixed dyslipidemia or persistently elevated TRLs despite statin therapy”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Premisecitation

    In MUIR and SHASTA-2, plozasiran reduced TG by 50-60% and improved remnant cholesterol, non-HDL-C, and apoB, while modest, dose-dependent LDL-C increases were observed at higher doses.

    “In MUIR [119] and SHASTA-2 [120], plozasiran similarly reduced TG by 50–60% and improved remnant cholesterol, non–HDL-C, and apoB, while modest, dose-dependent LDL-C increases were observed at higher doses.”
    Quote in the paperSubstantial claim0 of 2 sources checked
    • cites [119] Ballantyne CM, Vasas S, Azizad M et al (2024) Plozasiran, an RNA interference agent targeting APOC3, for mixed hyperlipidemia. N Engl J Med 391(10):899–912. https://doi.org/10.1056/NEJMoa2404143 source
    • cites [120] Gaudet D, Pall D, Watts GF et al (2024) Plozasiran (ARO-APOC3) for severe hypertriglyceridemia: the SHASTA-2 randomized clinical trial. JAMA Cardiol 9(7):620–630. https://doi.org/10.1001/jamacardio.2024.0959 source

  • May combine two claims.

    Premisereasoning

    Evinacumab favorably influences non-HDL cholesterol, ApoB, and remnant lipoproteins.

    “evinacumab favorably influences non-HDL cholesterol, ApoB, and remnant lipoproteins”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Premisecitation

    Evinacumab has shown compelling efficacy in reducing TG levels and addressing residual cardiovascular risk in select patient populations.

    “evinacumab, a fully human monoclonal antibody against ANGPTL3, has shown compelling efficacy in reducing TG levels and addressing residual cardiovascular risk in select patient populations”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Premisenone given

    Evinacumab was well tolerated, with lower rates of adverse events than placebo.

    “was well tolerated, with lower rates of adverse events than placebo”
    Quote in the paperNot a substantial claim

  • May combine two claims.

    Interpretationreasoning

    Olezarsen has broad metabolic efficacy, consistent safety, and potential for reducing both pancreatitis and residual atherosclerotic risk.

    “confirm olezarsen’s broad metabolic efficacy, consistent safety, and potential for reducing both pancreatitis and residual atherosclerotic risk”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Premisecitation

    Conventional therapies such as fibrates modestly reduce apoC-III, but the degree of suppression is limited and has not translated into consistent cardiovascular benefit.

    “apoC-III has long been recognized as a regulator of triglyceride metabolism and is modestly reduced by conventional therapies such as fibrates, the degree of suppression achieved with these agents is limited and has not translated into consistent cardiovascular benefit [113]”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [113] Tramontano D, Bini S, D’Erasmo L, Arca M (2022) Recent apolipoprotein CIII trials. Curr Opin Lipidol 33(6):309–318. https://doi.org/10.1097/MOL.0000000000000849 source
78 of 78

  • The paper relies on this without support.

    Lowering triglyceride-rich lipoproteins reduces cardiovascular risk.

    “This consistent signal across methodologies provides a strong rationale for therapeutic strategies aimed at reducing TRL burden through enhanced lipolysis, remnant clearance, or inhibition of key modulators such as APOC3 and ANGPTL3/4.”

  • The paper relies on this without support.

    The causal relationship between genetically elevated TRLs and ASCVD can be extrapolated to pharmacological lowering of TRLs.

    “Collectively, both observational and genetic evidence converge to support a causal link between TRL/remnant cholesterol and atherosclerotic cardiovascular disease.”

  • The paper relies on this without support.

    In patients with chronic kidney disease, hypertriglyceridemia is common and they are a high-risk population.

    “Patients with chronic kidney disease represent a high-risk population in whom hypertriglyceridemia is common”

  • The paper relies on this without support.

    DHA has been shown in some studies to modestly increase LDL-C levels, potentially offsetting some of EPA's anti-inflammatory and lipid-modifying benefits.

    “Notably, DHA has been shown in some studies to modestly increase LDL-C levels, potentially offsetting some of EPA's anti-inflammatory and lipid-modifying benefits.”

  • The paper relies on this without support.

    DHA has counteractive effects on LDL-cholesterol and membrane structure.

    “the absence of DHA in IPE avoids potential counteractive effects of DHA on LDL-cholesterol and membrane structure”

  • The paper relies on this without support.

    Most available studies of volanesorsen have been conducted in rare monogenic disorders.

    “most available studies have been conducted in rare monogenic disorders”
6 of 6

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

  • Gao study's hazard ratio points opposite to the stated risk direction

    Major

    The table says higher remnant cholesterol increased MACE risk, but its reported HR of 0.61 per 1-SD increase indicates lower risk.

  • Plozasiran is classified as both an antisense oligonucleotide and siRNA

    Minor

    The abstract groups plozasiran with antisense oligonucleotides, but the therapy section identifies it as a small interfering RNA.

2 of 2

Cites

Flagged first, then by citations

Research works printed but not linked: 5

  1. Camera XM, Toschi V, Comparato C, Baetta R, Tremoli E (2003) Triglyceride-rich lipoproteins activate tissue factor expression in human monocytes and endothelial cells. Circulation 108(21):260–266. https://doi.org/10.1161/01.CIR.0000097111.90847.7A · DOI
  2. Davidson MH (2006) Safety profile of fenofibrate. Am J Cardiol 97(2A):19C – 24
  3. Pimpin L et al (2016) The effect of omega-3 fatty acids on endothelial function: A systematic review and meta-analysis. Atherosclerosis 249:53–63
  4. Serhan CN et al (2015) Specialized pro-resolving mediators in the resolution of inflammation. Science 369(6509):1080–1086
  5. Miller PE et al (2014) Omega-3 fatty acids and cardiovascular disease: A review of the evidence. AHA J 34(9):1073–1084. https://doi.org/10.1161/ATVBAHA.114.303329 · DOI

Authors
Maiorca, C., Tramontano, D., Di Costanzo, A., & D’Erasmo, L.
Affiliations
  • ASL Roma (IT)
  • Sapienza University of Rome (IT)
Corresponding author
Maiorca, Carlo
ORCID
Venue
Internal and Emergency Medicine
Publisher
Springer Science and Business Media LLC
Published
2026-05-18
Volume
21
Issue
6
Pages
1961-1977
ISSN
  • 1828-0447 (ISSN-L)
  • 1970-9366
DOI
10.1007/s11739-026-04383-1
PMC
PMC13582088
OpenAlex
W7161553369
Semantic Scholar
813c95e89c9f7d0442898c16304580e19e0170de
Cited by
0
References
115
FWCI
0.00
Type
journal article
Language
en
Open access
Licence
Locations
  • Internal and Emergency Medicine (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PubMed Central (submittedVersion, cc-by)
  • IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
Funders
Università degli Studi di Roma La Sapienza
Topics
  • Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
triglyceride-rich lipoproteins, hypertriglyceridemia, residual cardiovascular risk, atherosclerotic cardiovascular disease, remnant cholesterol, icosapent ethyl, fibrates, omega-3 fatty acids, evinacumab, apolipoprotein C-III, volanesorsen, olezarsen, plozasiran, atherogenesis, plaque progression
MeSH terms
Heart Disease Risk Factors, Hypolipidemic Agents, Cardiovascular Diseases, Humans, Lipoproteins, Triglycerides, Hypertriglyceridemia, Risk Reduction Behavior

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Claims read by deepseek-v4.1-flash under definition version 3 (extract-v3) on 2026-10-19.

Classified by jev-1.13-20260917 (gold-guideline-v0.2) on 2026-10-19.

Cited sources are checked by gpt-6-sol.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review